Dec. 8 at 9:21 AM
$SRZN we also still have some very interesting drugs in preclinical stage which big pharma could restart to develop if they want. Like this drug against bone loss or bone regeneration:https://pmc.ncbi.nlm.nih.gov/articles/PMC8167098/
The drug that is already approved against bone loss is Amgen's Evenity (romosozumab) and it was estimated to generate peak sales of
$500 million. Now it is making
$541 million in Q3 2025 alone.
The drug is also interesting because it indirectly activates Wnt signaling by blocking a negative regulator, sclerostin. In the research article they showed that combining this drug with one of our WNT drugs could be even better.
And this is just one example. We also have something for the lung:https://pmc.ncbi.nlm.nih.gov/articles/PMC10985870/
Lacrimal Gland:https://pmc.ncbi.nlm.nih.gov/articles/PMC12165264/
